To our knowledge, this is the first IgE to show both in vitro and in vivo efficacy against a hematological cancer, more specifically a plasma cell cancer (in an aggressive disseminated murine model) and the first to target CD38. Here, CD38 is linked to hematopoietic and lymphoid cell neoplasm.